[(N-methyl-N-phenyl)amino]sulfonyl chloride | 85599-75-3

• 分子结构分类: 有机化合物 - 苯类化合物 - 苯和取代衍生物
• 英文名称: [(N-methyl-N-phenyl)amino]sulfonyl chloride
• 英文别名: methyl(phenyl)sulfamoyl chloride；N-methyl-N-phenylsulfamoyl chloride
• CAS: 85599-75-3
• 化学式: C₇H₈ClNO₂S
• 分子量: 205.665
• InChiKey: QGPPUNWBERCJQO-UHFFFAOYSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  1.8
• 重原子数：
  12
• 可旋转键数：
  2
• 环数：
  1.0
• sp3杂化的碳原子比例：
  0.14
• 拓扑面积：
  45.8
• 氢给体数：
  0
• 氢受体数：
  3

反应信息

• 作为反应物：
  描述：

  [(N-methyl-N-phenyl)amino]sulfonyl chloride 在 苄基三乙基氯化铵 水 、 sodium carbonate 作用下， 以 苯 为溶剂， 反应 5.0h， 以44%的产率得到N-Methyl-N-phenylsulfamat
  参考文献：
  名称：

  Synthesis of Arylsulfamic Acid Esters using Phase-Transfer and Triethylamine-Mediated Methods

  摘要：

  DOI：

  10.1055/s-1983-30225

文献信息

• [EN] DIARYL ETHER DERIVATIVES AS NOTCH SPARING GAMMA SECRETASE INHIBITORS<br/>[FR] DÉRIVÉS D'ÉTHER DIARYLIQUE COMME INHIBITEURS DE LA GAMMA-SÉCRÉTASE N'AGISSANT PAS SUR LA VOIE NOTCH
  申请人：MERCK SHARP & DOHME

  公开号：WO2011046774A1

  公开（公告）日：2011-04-21

  The invention encompasses a novel class of diaryl ether derivatives which inhibit the processing of APP by the putative ϒ-secretase while sparing Notch signaling pathway, and thus are useful in the treatment or prevention of Alzheimer's disease without the development of Notch inhibition mediated gastrointestinal issues. Pharmaceutical compositions and methods of use are also included.

  这项发明涵盖了一类新颖的二芳基醚衍生物，可以抑制假定的ϒ-分泌酶对APP的加工，同时保留Notch信号通路，因此在治疗或预防阿尔茨海默病时非常有用，而不会导致Notch抑制介导的胃肠问题的发展。药物组合物和使用方法也包括在内。
• [EN] NOVEL SULFAMIDE PIPERAZINE DERIVATIVES AS PROTEIN TYROSINE KINASE INHIBITORS AND PHARMACEUTICAL USE THEREOF<br/>[FR] NOUVEAUX DÉRIVÉS DE SULFAMIDE PIPÉRAZINE À TITRE D'INHIBITEURS DE PROTÉINES TYROSINE KINASES ET LEUR UTILISATION PHARMACEUTIQUE
  申请人：LEO PHARMA AS

  公开号：WO2012093169A1

  公开（公告）日：2012-07-12

  The invention relates to compounds of general Formula (I), Wherein R1, R2, R3, R4, R5, m, n are defined herein, and pharmaceutically acceptable salts, prodrugs, hydrates, or solvates thereof, for use - alone or in combination with one or more other pharmaceutically active compounds- in therapy, as JAK kinase and protein tyrosine kinase inhibitors for preventing, treating or ameliorating diseases and complications thereof, including, for example, psoriasis, atopic dermatitis, rosacea, lupus, multiple sclerosis, rheumatoid arthritis, Type I diabetes, asthma, cancer, autoimmune thyroid disorders, ulcerative colitis, Crohn's disesase, Alzheimer's disease, leukaemia, eye diseases such as diabetic retinopathy and macular degeneration as well as other autoimmune diseases and indications where immunosuppression would be desirable for example in organ transplantation.

  该发明涉及一般式(I)的化合物，其中R1、R2、R3、R4、R5、m、n在此处定义，并且其药用可接受的盐、前药、水合物或溶剂化合物，用于单独或与一个或多个其他药用活性化合物结合在一起，在治疗中使用，作为JAK激酶和蛋白酪氨酸激酶抑制剂，用于预防、治疗或改善疾病及其并发症，包括例如牛皮癣、特应性皮炎、酒渣鼻、狼疮、多发性硬化症、类风湿关节炎、I型糖尿病、哮喘、癌症、自身免疫性甲状腺疾病、溃疡性结肠炎、克罗恩病、阿尔茨海默病、白血病、眼部疾病如糖尿病视网膜病变和黄斑变性以及其他自身免疫性疾病和免疫抑制希望的适应症，例如在器官移植中。
• [EN] CYSTEINE BINDING COMPOSITIONS AND METHODS OF USE THEREOF<br/>[FR] COMPOSITIONS DE LIAISON À LA CYSTÉINE ET LEURS PROCÉDÉS D'UTILISATION
  申请人：UNIV VIRGINIA PATENT FOUNDATION

  公开号：WO2021016263A1

  公开（公告）日：2021-01-28

  Purine-derived covalent probes (e.g., halo or di-halo-substituted purine based covalent probes) and related ligands are described. The compounds can be used to identify reactive nucleophilic amino acid residues, such as reactive cysteine residues, in proteins and to modify the activity of proteins with reactive nucleophilic amino acid residues (e.g., reactive cysteine residues) via the formation of protein adducts comprising the ligands. Modified proteins prepared from the probes and ligands are also described.

  描述了嘌呤衍生的共价探针（例如，基于卤素或二卤代嘌呤的共价探针）和相关配体。这些化合物可用于识别蛋白质中的反应性亲核氨基酸残基，例如反应性半胱氨酸残基，并通过形成包含配体的蛋白质加合物来修改具有反应性亲核氨基酸残基（例如，反应性半胱氨酸残基）的蛋白质的活性。还描述了从探针和配体制备的修饰蛋白质。
• Sulfamide derivatives useful as beta3 agonists and pharmaceutical uses thereof
  申请人：Pfizer Products Inc.

  公开号：EP1236723A1

  公开（公告）日：2002-09-04

  Sulfamide compounds having formula (I) are described as well as their use in the treatment of diseases dependent on the signaling pathways associated with β-adrenergic receptors, such as obesity, diabetes, hypertension, gastrointestinal hypo- or hyper-motility and cardiovascular diseases.

  公式（I）的磺胺化合物被描述，并且它们被用于治疗依赖于与β-肾上腺素受体相关的信号通路的疾病，例如肥胖症、糖尿病、高血压、胃肠道低动力或高动力以及心血管疾病。
• [EN] SULFAMIDE DERIVATIVES AND PHARMACEUTICAL COMPOSITION FOR UPREGULATION OF LIPID METABOLISM COMPRISING SAME<br/>[FR] DERIVES DE SULFAMIDE ET COMPOSITION PHARMACEUTIQUE SERVANT A REGULER POSITIVEMENT LE METABOLISME DES LIPIDES ET CONTENANT CES DERIVES
  申请人：CRYSTALGENOMICS INC

  公开号：WO2006006832A1

  公开（公告）日：2006-01-19

  The present invention relates to a novel sulfamide derivative, a pharmaceutically acceptable salt thereof and a pharmaceutical composition for upregulation of lipid metabolism comprising same as an active ingredient.

  本发明涉及一种新型磺胺酰胺衍生物，其药用可接受的盐以及一种含有其作为活性成分的用于上调脂质代谢的制药组合物。